Background & Aims Seroclearance of hepatitis B surface antigen (HBsAg) is a marker for
clearance of chronic hepatitis B virus (HBV) infection, but reported annual incidence rates of …

Summary Background Spontaneous loss of HBsAg (known as functional cure) in patients
with chronic hepatitis B virus (HBV) infection significantly reduces liver-related …

Background The seroclearance of hepatitis B surface antigen (HB sAg) in patients with
chronic hepatitis B (CHB) is considered to be associated with favourable clinical outcomes …

Hepatitis B surface antigen (HBsAg) seroclearance is regarded as the ideal endpoint for
antiviral treatment. However, reports on the durability of and outcomes after HBsAg …

Background Although hepatitis B surface antigen (HBsAg) loss is considered the ideal
therapeutic endpoint for the treatment of chronic hepatitis B virus (HBV) infection, its impact …

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading
cause of cancer-related death worldwide. Hepatitis B virus (HBV) infection is among the …

There is no consensus about factors that increase risk of hepatocellular carcinoma (HCC)
among patients with chronic hepatitis B who have achieved seroclearance of hepatitis B …

Biochemical response is an important prognostic indicator in chronic hepatitis B (CHB)
patients receiving nucleotide/nucleoside analogues (NAs). However, the effects of air …

Hepatitis B surface antigen (HBsAg) clearance is regarded as the ideal endpoint for antiviral
treatment in terms of drug withdrawal safety and improvements in prognosis. However, the …

Chronic hepatitis B (CHB) is a major global health challenge. CHB can be controlled by
antivirals but a therapeutic cure is lacking. CHB is characterized by limited HBV-specific T …